Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US11879014B2 · kind B2 · utility
0Cited by
2References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 3, 2018 |
| Grant date | Jan 23, 2024 |
| Priority date | — |
| Expiry date | Jun 27, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.